# GO Capital Fund

> GO Capital Fund is a VC fund in Montréal backing Software and Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 6
- Last investment: Sep 2024
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/investissement-quebec
- X (Twitter): https://www.twitter.com/investquebec
- Website: http://www.fierpartenaires.com/en/portfolio.htm#go_capital

GO Capital Fund is a VC fund in Montréal focused on Software and Biotechnology. GO Capital is a $50 million venture capital fund intended to support young Quebec technology firms in search of financing, particularly firms working in the fields of advanced technologies, information technology, life sciences and telecommunications.GO Capital investments in the selected firms will match, dollar for dollar, the investments byBDC, bringing the available capital to $100 million.FIER Partners has undertaken to invest $25 million taken in the new stream of seed funding for technology firms in Go Capital. The remaining capital is being provided by the BDC ($10 million), the Caisse de dépôt et placement du Québec ($10 million), the Solidarity Fund QFL ($3 million) and Fondaction, the CSN's development fund for co-operation and employment ($2 million).

## Contacts

5 contacts available for GO Capital Fund. Shizune tracks 7 team members at GO Capital Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/go-capital-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 33% |
| Biotechnology | 2 | 33% |
| Mobile | 1 | 17% |
| Hardware | 1 | 17% |
| Analytics | 1 | 17% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |
| Convertible Note | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 3 | 50% |
| United States | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Charles Cazabon | Managing Partner | 0 | — |
| Charles Sylvestre | Director | 0 | — |
| Gérald St-Aubin | Director | 0 | — |
| Jocelyne Marquis | Director | 0 | — |
| Luc Villeneuve | Director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rimsys | Rimsys is a world-leading Regulatory Information Management (RIM) software for medical technology companies. Built by and for regulatory affairs professionals, Rimsys digitizes, automates, and creates regulatory order to ensure products adhere to changing global regulations. It is the only holistic RIM software for medical devices, in-vitrodiagnostics, and medical device software that makes it easy to manage global UDI requirements and navigate the pillars of regulatory affairs, including product registration, standards management, essential principles/GSPR, and regulatory intelligence. | $5M | Venture - Series Unknown | Sep 30, 2024 |  |
| LeddarTech | LeddarTech provides the most flexible, robust and accurate sensing technology for advanced driver assistance systems (ADAS) and autonomous driving (AD). Our solutions enable customers to solve critical environmental sensing, fusion and perception challenges across the entire value chain.The company develops cost-effective perception solutionsscalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types (camera, radar and LiDAR) and configurations.LeddarTech’s disruptive technology reduces risks, accelerates development cycles and enables faster time-to-market. We are responsible for several cutting-edge remote-sensing innovations, with over 140 patents granted or applied for that enhance ADAS and autonomous driving capabilities.Our customers are OEMs and Tier 1-2 automotive suppliers looking for sensing and perception solutions that allow them to meet their key performance, cost and development time requirements for faster time-to-market and ROI. | $11.6M | Convertible Note | Nov 20, 2018 |  |
| Alethia BioTherapeutics | Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $4.7M | Series B | Nov 02, 2012 |  |
| Neuralitic Systems | Neuralitic Systems' helps mobile service operators understand the mobile data user behaviours that influence data service adoption, so that they can automatically uncover new trends and habits and dynamically leverage these emerging behaviours to ignite data revenue growth. | $8.1M | Series C | Jan 31, 2011 |  |
| Alethia BioTherapeutics | Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M | Series A | Sep 07, 2010 |  |
| Allostera Pharma | Allostera Pharma is a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes. | $12.4M | Series A | Jul 08, 2009 |  |

6 of 6 investments shown.

## Co-investors
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 5 deals together
- AgeChem Venture Fund — VC Fund, 2 deals together
- [BDC Healthcare Venture](https://shizune.co/investors/profile/bdc-healthcare-fund) — VC Fund, 1 deal together
- BlackBerry Partners Fund — VC Fund, 1 deal together
- [Delphi Ventures](https://shizune.co/investors/profile/delphi-ventures) — VC Fund, 1 deal together
- [Desjardins-Innovatech](https://shizune.co/investors/profile/desjardins-innovatech) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does GO Capital Fund invest in?

GO Capital Fund invests primarily in Software, Biotechnology and Mobile startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact GO Capital Fund?

Public channels for GO Capital Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at GO Capital Fund?

The team at GO Capital Fund includes Charles Cazabon (Managing Partner), Charles Sylvestre (Director) and Gérald St-Aubin (Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co